American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 13, 2017, American Renal Associates Holdings, Inc. (the “Company”) entered into a First Amendment to Employment Agreement (the “Amendment”) with its Chief Financial Officer, Jon Wilcox. The Amendment provides for an increase in his annual base salary, effective January 1, 2018, to $450,000 from his current base salary of $424,999.90. The base salary is subject to such further increases as may be approved from time to time by the Company.
In addition, to the Amendment, Mr. Wilcox received a grant of 24,922 shares of restricted stock and an option to purchase 25,166 shares of the Company’s common stock at an exercise price of $16.05 per share, in each case subject to vesting in three equal annual installments beginning December 13, 2018.
Except as described above, all other terms of Mr. Wilcox’s employment agreement remain unchanged. The foregoing description of theAmendmentis not complete and is subject to and qualified in its entirety by reference to the full text of theAmendment, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Financial Statements and Exhibits.
American Renal Associates Holdings, Inc. ExhibitEX-10.1 2 firstamendmenttoemployment.htm EXHIBIT 10.1 Exhibit Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENTThis FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”) is entered into effective as of December 13,…To view the full exhibit click
About American Renal Associates Holdings, Inc. (NYSE:ARA)
American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.
An ad to help with our costs